Amarantus Appoints Dr. Charlotte Keywood Chief Medical Officer of Its Therapeutics Division
April 08 2014 - 6:00AM
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology
company focused on the discovery and development of novel
diagnostics and therapeutics related to cell cycle dysregulation,
endoplasmic reticulum stress, neurodegeneration and apoptosis,
today announced the appointment of Charlotte Keywood, MD, as Chief
Medical Officer of the Company's therapeutics division. Dr. Keywood
brings over 20 years of experience in the biopharmaceutical drug
development industry, including the development of Parkinson's
disease Levadopa-Induced Dyskynesia (PD LID) drug candidates.
"I am very pleased to be joining the team at Amarantus to lead
the clinical development programs of Eltoprazine and MANF," said
Dr. Keywood, Amarantus' newly appointed Chief Medical Officer.
"Eltoprazine has an attractive profile for a number of potential
central nervous system indications. We intend to focus initially on
the clinical study planning for Eltoprazine in PD LID and Adult
ADHD, based on the successful Phase 2a data that were previously
reported in these indications."
Dr. Keywood's experience in the pharmaceutical industry includes
running European and US pre- and post-registration clinical
development programs across a broad range of therapeutic areas, as
well as medical marketing and pharmacovigilance activities. Most
recently, she was CMO at Addex Pharma, for ten years, overseeing
clinical development of the company's allosteric modulator
programs. Dr. Keywood served from 2001 to 2003 as medical director
for Axovan, a Swiss biotech company that was acquired by Actelion
in 2003. From 1996 to 2001 she was medical director at Vernalis,
where she helped bring a new migraine drug, Frova frovatriptan, to
the market. From 1991 to 1996 she was medical director of the
European subsidiary of US biotechnology company Gensia. Dr Keywood
is a cardiologist who completed her post-graduate training at St
Thomas' Hospital, London.
"Dr. Keywood brings tremendous clinical drug development
experience to Amarantus, particularly in the area of PD LID," said
Gerald E. Commissiong, President & CEO of Amarantus. "We
believe this experience will be of great value to Amarantus as we
prepare to continue the development of Eltoprazine into Phase 2b
clinical trials, given her stellar track record in PD LID liaising
with Key Opinion leaders and clinical sites and her strong
relationships within the community. Dr. Keywood is an excellent
addition to our team and will work closely with Dr. David Lowe to
execute our clinical strategy."
About Amarantus
Amarantus is a biotechnology company developing treatments and
diagnostics for diseases associated with neurodegeneration and
protein misfolding-related apoptosis. The Company has licensed
Eltoprazine ("Eltoprazine"), a phase 2b ready indication for
Parkinson's Levodopa induced dyskinesia and Adult ADHD. The Company
has an exclusive worldwide license to the Lymphocyte Proliferation
test ("LymPro Test(R)") for Alzheimer's disease and owns the
intellectual property rights to a therapeutic protein known as
Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is
developing MANF-based products as treatments for brain disorders.
Amarantus is a Founding Member of the Coalition for Concussion
Treatment (#C4CT), a movement initiated in collaboration with
Brewer Sports International seeking to raise awareness of new
treatments in development for concussions and nervous-system
disorders. The Company also owns intellectual property for the
diagnosis of Parkinson's disease ("NuroPro") and the discovery of
neurotrophic factors ("PhenoGuard"). For further information please
visit www.Amarantus.com, or connect with the Company on Facebook,
LinkedIn, Twitter and Google+.
Certain statements, other than purely historical information,
including estimates, projections, statements relating to our
business plans, objectives, and expected operating results, and the
assumptions upon which those statements are based, are
forward-looking statements. These forward-looking statements
generally are identified by the words "believes," "project,"
"expects," "anticipates," "estimates," "intends," "strategy,"
"plan," "may," "will," "would," "will be," "will continue," "will
likely result," and similar expressions. Forward-looking statements
are based on current expectations and assumptions that are subject
to risks and uncertainties which may cause actual results to differ
materially from the forward-looking statements. Our ability to
predict results or the actual effect of future plans or strategies
is inherently uncertain. Factors which could have a material
adverse effect on our operations and future prospects on a
consolidated basis include, but are not limited to: changes in
economic conditions, legislative/regulatory changes, availability
of capital, interest rates, competition, and generally accepted
accounting principles. These risks and uncertainties should also be
considered in evaluating forward-looking statements and undue
reliance should not be placed on such statements.
CONTACT: Investor/Media Contacts
Aimee Boutcher, Director of Investor Relations
Amarantus Bioscience Holdings, Inc.
408-737-2734 x 101
ir@amarantus.com
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2023 to Apr 2024